Zhejiang Anglikang Pharmaceutical Co Ltd Class A (002940) — Tangible Net Worth Ratio
Zhejiang Anglikang Pharmaceutical Co Ltd Class A (002940) has a Tangible Net Worth Ratio of 91.1% as of June 2026. This metric is calculated by deducting intangible assets (CN¥169.49 Million) from net assets (CN¥1.90 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Also explore Zhejiang Anglikang Pharmaceutical Co Ltd annual equity growth to track the company's year-over-year net asset growth rate.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Zhejiang Anglikang Pharmaceutical Co Ltd Class A Tangible Net Worth Ratio (2014–2025)
This chart shows how Zhejiang Anglikang Pharmaceutical Co Ltd Class A's Tangible Net Worth Ratio has changed across 12 annual periods from 2014 to 2025. As of June 2026, the ratio stands at 91.1%, reflecting net assets of CN¥1.90 Billion with intangible assets of CN¥169.49 Million CNY. For live market cap and overall valuation, see 002940 market cap overview.
Annual Tangible Net Worth Ratio for Zhejiang Anglikang Pharmaceutical Co Ltd Class A (2014–2025)
The table below presents the year-by-year Tangible Net Worth Ratio for Zhejiang Anglikang Pharmaceutical Co Ltd Class A from 2014 to 2025, covering 12 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. Explore Zhejiang Anglikang Pharmaceutical Co Ltd capex to cash flow ratio to see what proportion of operating cash flow is directed to capital expenditures.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 90.7% | CN¥1.87 Billion | CN¥173.68 Million | CN¥2.95 Billion | ▲ +0.6 pp |
| 2024 | 90.1% | CN¥1.80 Billion | CN¥178.73 Million | CN¥2.97 Billion | ▼ -0.8 pp |
| 2023 | 90.8% | CN¥1.83 Billion | CN¥168.14 Million | CN¥3.02 Billion | ▼ -6.8 pp |
| 2022 | 97.6% | CN¥1.65 Billion | CN¥38.78 Million | CN¥2.60 Billion | ▲ +0.4 pp |
| 2021 | 97.3% | CN¥1.47 Billion | CN¥40.05 Million | CN¥2.08 Billion | ▼ 0.0 pp |
| 2020 | 97.3% | CN¥1.38 Billion | CN¥36.88 Million | CN¥1.94 Billion | ▲ +1.1 pp |
| 2019 | 96.2% | CN¥1.02 Billion | CN¥38.87 Million | CN¥1.38 Billion | ▲ +0.3 pp |
| 2018 | 95.9% | CN¥970.93 Million | CN¥40.15 Million | CN¥1.47 Billion | ▲ +6.5 pp |
| 2017 | 89.4% | CN¥394.37 Million | CN¥41.89 Million | CN¥906.78 Million | ▲ +2.7 pp |
| 2016 | 86.6% | CN¥327.43 Million | CN¥43.75 Million | CN¥727.99 Million | ▲ +3.9 pp |
| 2015 | 82.7% | CN¥264.20 Million | CN¥45.68 Million | CN¥799.83 Million | ▲ +5.2 pp |
| 2014 | 77.5% | CN¥217.08 Million | CN¥48.82 Million | CN¥731.44 Million | — |